Group items tagged

The Jane Coffin Childs Memorial Fund for Medical Research was established in 1937 for the purpose of supporting research into the causes and treatment of cancer. The fund has taken a broad approach to the study of cell growth and development, emphasizing the study of the basic biology and chemistry of the underlying processes, and increasingly has focused its resources on the funding of three-year postdoctoral fellowships, supporting fellows selected by its board of scientific advisers from among the best young scientists at what is often a critical stage in their careers. As a result, there have been more than sixteen hundred Jane Coffin Childs fellows doing basic cancer-related research in laboratories in North America, Europe, Japan, and Australia.

The Jane Coffin Childs Memorial Fund for Medical Research was established in 1937 for the purpose of supporting research into the causes and treatment of cancer. The fund has taken a broad approach to the study of cell growth and development, emphasizing the study of the basic biology and chemistry of the underlying processes, and increasingly has focused its resources on the funding of three-year postdoctoral fellowships, supporting fellows selected by its board of scientific advisers from among the best young scientists at what is often a critical stage in their careers. As a result, there have been more than sixteen hundred Jane Coffin Childs fellows doing basic cancer-related research in laboratories in North America, Europe, Japan, and Australia. To advance its mission, the JCC Fund is accepting applications for its fellowship program. The fund supports between twenty-five and thirty new three-year cancer research fellowships every year. The current fellowship stipend levels are $52,000 for year one; $52,500 for year two; and $53,000 for year three.

The Jane Coffin Childs Memorial Fund for Medical Research was established in 1937 for the purpose of supporting research into the causes and treatment of cancer. The fund has taken a broad approach to the study of cell growth and development, emphasizing the study of the basic biology and chemistry of the underlying processes. It has increasingly focused its resources on the funding of three-year postdoctoral fellowships, supporting fellows selected from among the best young scientists at what is often a critical stage in their careers.

The purpose of this Funding Opportunity Announcement (FOA) is to promote collaborative biomedical research between the United States and Brazil under the U.S.-Brazil Biomedical Collaborative Research Program. Research areas supported under this program include allergy, immunology, and infectious diseases, including HIV/AIDS and its co-morbidities; cancer; mother-to-child transmission of HIV and other congenital infections, early infant diagnosis and treatment; HIV/AIDS in relation to mental health; and neurological disorders and stroke.

The purpose of this funding opportunity is to establish a program of research to advance the understanding, prevention and treatment of pediatric multiple organ dysfunction syndrome (MODS). Given the prevalence and associated morbidity and mortality of MODS in children, the current lack of understanding underscores the need for more exploratory research. Possible topics of study include, but are not limited to, the epidemiology, pathophysiology, monitoring, and treatment of MODS. Studies that assess specific etiologies associated with MODS including, but not limited to, sepsis, trauma, acute respiratory distress syndrome, inborn errors of metabolism, burns, cancer, transplantation and congenital heart disease are encouraged. Applications may include any appropriate study design ranging from basic science animal models through small prospective randomized controlled trials. The intent of this R21 funding initiative is to encourage exploratory and developmental research projects by providing support for the early and conceptual stages of research projects addressing these topics. These studies may incur considerable research risk in efforts to make important breakthroughs in the understanding, prevention and treatment of MODS in children. Projects of limited cost or scope that use widely accepted approaches and methods within well-established fields are better suited for the R03 small grant activity code. It is hoped that the results of this exploratory research will translate into improved clinical outcomes for children with, and at risk for MODS.

The purpose of this Funding Opportunity Announcement (FOA) is to invite applications for research projects designed to use sound and innovative strategies to solve specific problems and paradoxes in childhood cancer research identified by the National Cancer Institute (NCI) as the NCIs Pediatric Provocative Questions (Pediatric PQs). These problems and paradoxes framed as questions are not intended to represent the full range of NCI's priorities in childhood cancer research. Rather, they are meant to challenge cancer researchers to think about and elucidate specific problems in key areas of pediatric cancer research that are deemed important but have not received sufficient attention.

The Research Project Grant (R01) supports a discrete, specified, circumscribed project to be performed by the named investigator(s) in areas representing the specific interests and competencies of the investigator(s). The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on descriptions of their programs.

As part of the Gabriella Miller Kids First Pediatric Research Program (Kids First), the NIH invites applications to use whole genome sequencing at a Kids First-supported sequencing center to elucidate the genetic contribution to childhood cancers, and to investigate the genetic etiology of structural birth defects.These data will become part of the Gabriella Miller Kids First Pediatric Data Resource (Kids First Data Resource) for the pediatric research community.

Alex's Lemonade Stand Foundation is dedicated to raising money and awareness of the causes of childhood cancer. The foundation emerged from the front-yard lemonade stand of four-year-old Alexandra "Alex" Scott, who while fighting cancer herself wanted to raise money to find cures for all children with cancer. Her spirit and determination was inspirational, and by her untimely death at the age of 8, Alex had helped raise $1 million. Today, ALSF is one of the leading funders of pediatric cancer research in the United States and Canada. To advance its mission, ALSF is currently accepting applications for its Reach Grants program, which seeks to remove barriers to the transition of ideas from the pre-clinic stage to a clinical setting. To that end, grants of $250,000 over two years will be awarded to developmental therapeutic studies in the late stage of preclinical testing. Preference will be given to research projects that, if funded, will likely result in the initiation of a clinical trial two to three years from the start of the project. Funded projects must be focused on childhood cancers.

Alex's Lemonade Stand Foundation, a nonprofit foundation that has evolved from a young cancer patient's front yard lemonade stand to a national foundation for childhood cancer, awards grants designed to fill critical voids in current pediatric cancer research. Through its Innovation Grants program, the foundation awards two-year grants of up to $250,000 in support of researchers with a novel approach to pediatric oncology investigation. This can include a change in research direction and/or an innovative new idea that moves away from an investigator's prior research but has potential impact for childhood cancers. Innovation Grants will support research proposals to be carried out by investigators who are already established, have a track record of peer-reviewed publications, and can demonstrate evidence of successfully competing for extramural funding. To be eligible, applicants must possess a degree at the MD, MD/PhD or PhD level and hold a faculty appointment at an academic institution.

REISSUE of PAR-18-733 The NIH Common Fund has established the Gabriella Miller Kids First Pediatric Research Program (Kids First) to develop a pediatric research data resource populated by genome sequence and phenotype data that will be of high value for the communities of investigators who study the genetics of childhood cancers and/or structural birth defects. The overall goal of the Gabriella Miller Kids First Pediatric Data Resource is to help researchers understand the underlying mechanisms of these conditions, leading to more refined diagnostic capabilities and ultimately more targeted therapies, as well as to develop an integrated pediatric research data resource by obtaining and aggregating genome sequence and phenotype data for as many relevant structural birth defects and pediatric cancer cohorts as possible and to advance research in this area through the broad sharing of these data with the research community. This FOA is intended to promote meritorious small research projects focused on the development and analyses of childhood cancer and/or structural birth defects datasets that are part of the Kids First Data Resource or could be included in the Kids First Data Resource. Development of statistical methodology appropriate for analyzing genome-wide data relevant to childhood cancer and/or structural birth defects may also be proposed.

The purpose of this Funding Opportunity Announcement (FOA) is to invite applications for research projects designed to use sound and innovative strategies to solve specific problems and paradoxes in childhood cancer research identified by the National Cancer Institute (NCI) as the NCIs Pediatric Provocative Questions (Pediatric PQs). These problems and paradoxes framed as questions are not intended to represent the full range of NCI's priorities in childhood cancer research. Rather, they are meant to challenge cancer researchers to think about and elucidate specific problems in key areas of pediatric cancer research that are deemed important but have not received sufficient attention.

This Funding Opportunity Announcement (FOA) encourages research on how the healthcare delivery system enhances or inhibits the effectiveness of a provider's recommendation of the adolescent human papillomavirus (HPV) vaccine. Characteristics of the provider, parent/patient, and clinical setting, can all affect whether a provider makes a recommendation, and whether that recommendation results in uptake of the HPV vaccine. This research requires expertise in cancer prevention, adult and childhood behavior, immunization promotion, and healthcare delivery.

This Funding Opportunity Announcement (FOA) encourages research on how the healthcare delivery system enhances or inhibits the effectiveness of a provider's recommendation of the adolescent human papillomavirus (HPV) vaccine. Characteristics of the provider, parent/patient, and clinical setting, can all affect whether a provider makes a recommendation, and whether that recommendation results in uptake of the HPV vaccine. This research requires expertise in cancer prevention, adult and childhood behavior, immunization promotion, and healthcare delivery.

This Funding Opportunity Announcement (FOA) encourages research on how the healthcare delivery system enhances or inhibits the effectiveness of a provider's recommendation of the adolescent human papillomavirus (HPV) vaccine. Characteristics of the provider, parent/patient, and clinical setting, can all affect whether a provider makes a recommendation, and whether that recommendation results in uptake of the HPV vaccine. This research requires expertise in cancer prevention, adult and childhood behavior, immunization promotion, and healthcare delivery.

As part of the Gabriella Miller Kids First Pediatric Research Program (Kids First), the NIH invites applications to submit samples from pediatric cohorts for whole genome sequencing at a Kids First-supported sequencing center. Applicants are encouraged to propose sequencing of existing pediatric cancer cohorts to elucidate the genetic contribution to childhood cancers, or to expand the range of disorders included within the Kids First Data Resource to investigate the genetic etiology of structural birth defects. Whole genome, exome, and transcriptome sequencing may be available for tumor or affected tissue when justified. These data, and associated clinical and phenotypic data, will become part of the Gabriella Miller Kids First Pediatric Data Resource (Kids First Data Resource) for the pediatric research community.

The purpose of this funding opportunity announcement (FOA) is to establish a program of research to advance the understanding, prevention and treatment of pediatric multiple organ dysfunction syndrome (MODS). Given the prevalence and associated morbidity and mortality of MODS in children, the current lack of understanding underscores the need for more basic, exploratory and longitudinal research. Possible topics of study include, but are not limited, to the epidemiology, pathophysiology, monitoring, and treatment of MODS. Studies that assess specific etiologies associated with MODS including, but not limited to, sepsis, trauma, acute respiratory distress syndrome, inborn errors of metabolism, burns, cancer, transplantation and congenital heart disease are encouraged. Applications may include any appropriate study designs ranging from basic science and animal models through prospective randomized controlled trials. It is hoped that as a result of research supported through this funding opportunity, outcomes will improve both in terms of the prevention and treatment of MODS in children.

This Funding Opportunity Announcement (FOA) encourages research on how the healthcare delivery system enhances or inhibits the effectiveness of a provider's recommendation of the adolescent human papillomavirus (HPV) vaccine. Characteristics of the provider, parent/patient, and clinical setting, can all affect whether a provider makes a recommendation, and whether that recommendation results in uptake of the HPV vaccine. This research requires expertise in cancer prevention, adult and childhood behavior, immunization promotion, and healthcare delivery.

This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. The purpose of this FOA is to establish Centers of collaborating investigators with the goal of identifying and advancing research opportunities for translating immunotherapy concepts for children and adolescents with cancer toward clinical applications. Specifically, this FOA targets the following area designated as a scientific priority by the Blue Ribbon Panel (BRP): Recommendation (B) that calls for the establishment of a pediatric immunotherapy translational science network. The network was envisioned by the BRP as focusing on identifying new targets for immunotherapies, developing new pediatric immunotherapy treatment approaches (e.g., cancer vaccines, cellular therapy, combinations of immunotherapy agents, and others), and defining the biological mechanisms by which pediatric tumors evade the immune system. The Pediatric Immunotherapy Discovery and Development Network (PI-DDN) Centers will address and implement these BRP recommendations.

A Kids' Brain Tumor Cure, a national non-profit organization, was founded in 2007 by a group of dedicated parents, physicians and friends to improve the treatment, quality of life, and long-term outlook for children with brain tumors through research, support, education, and advocacy. The number one priority of A Kids' Brain Tumor Cure Foundation is to act as a catalyst for researchers world-wide to turn their attention to the area of pediatric low grade glioma brain tumor research and to award research grants for the most promising programs and studies. Proposals related to basic and translational* projects that can advance understanding of the underlying biology of the development and treatment of PLGA tumors will be considered. Investigators in the early years of their careers are encouraged to apply.